Social/economic costs and health-related quality of life in patients with rare diseases in Europe

European Journal of Health Economics

Volumn 17, Issue , 2016, Pages 1-5

  López Bastida, Julio ^a,b   Oliva Moreno, Juan ^a,b   Linertová, Renata ^b,c   Serrano Aguilar, Pedro ^b,d  

^a UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^b Unidad Docente Multiprofesional de Atención Familiar y Comunitaria Oeste   (Spain)

^c Fundación Canaria de Investigación Sanitaria FUNCANIS   (Spain)

^d Evaluation and Planning Service at Canary Islands Health Service   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PATIENT; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DUCHENNE MUSCULAR DYSTROPHY; EDITORIAL; EPIDERMOLYSIS BULLOSA; EUROPE; FRAGILE X SYNDROME; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH PROGRAM; HEMOPHILIA; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LANGERHANS CELL HISTIOCYTOSIS; LIFE EXPECTANCY; MUCOPOLYSACCHARIDOSIS; PRADER WILLI SYNDROME; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RARE DISEASE; SCLERODERMA; COST OF ILLNESS; ECONOMICS; EUROPEAN UNION; RARE DISEASES; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA;

COST OF ILLNESS; EUROPE; EUROPEAN UNION; HEALTH CARE COSTS; HUMANS; QUALITY OF LIFE; RARE DISEASES; SOCIOECONOMIC FACTORS;

EID: 84962330037     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-016-0780-7     Document Type: Editorial

References (53)

1. Institute of Medicine of the National Academies. Rare diseases and orphan products. accelerating research and development. The National Academies Press (2010)
2. European Commission. Improving access to orphan medicines for all affected EU citizens. Available at: http://ec.europa.eu/pharmaphorum/docs/pricing_orphans_en.pdf
3. EUROSDIS. Rare diseases: Understanding this public health priority (2005). Available at: http://www.eurordis.org/publication/rare-diseases-understanding-public-health-priority
4. Fischer, A., Borensztein, P., Roussel, C.: The European rare diseases therapeutic initiative. PLoS Med. 2(9), e243 (2005)
5. Commission of the European Communities. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on Rare Diseases: Europe’s challenges Brussels, 11.11.2008. Available at: http://ec.europa.eu/health/ph_threats/non_com/docs/rare_com_en.pdf
6. Schieppati, A., Henter, J.I., Daina, E., Aperia, A.: Why rare diseases are an important medical and social issue. Lancet 371(9629), 2039–2041 (2008)
7. Denis A, Simoens S, Fostier C, Mergaert L, Cleemput I. Policies for orphan diseases and orphan drugs. health technology assessment (HTA). Brussels: Belgian Health Care Knowledge Centre (KCE); 2009. KCE reports 112C (D/2009/10.273/32)
8. Winter, Y., Schepelmann, K., Spottke, A.E., Claus, D., Grothe, C., Schröder, R., Heuss, D., Vielhaber, S., Tackenberg, B., Mylius, V., Reese, J.P., Kiefer, R., Schrank, B., Oertel, W.H., Dodel, R.: Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy. J. Neurol. 257(9), 1473–1481 (2010)
9. López-Bastida, J., Perestelo-Pérez, L., Montón-Alvarez, F., Serrano-Aguilar, P.: Social economic costs and health-related quality of life in patients with degenerative cerebellar ataxia in Spain. MovDisord. 23(2), 212–217 (2008)
10. López-Bastida, J., Perestelo-Pérez, L., Montón-Alvarez, F., Serrano-Aguilar, P., Alfonso-Sanchez, J.L.: Social economic costs and health-related quality of life in patients with amyotrophic lateral sclerosis in Spain. Amyotroph Lateral Scler. 10(4), 237–243 (2009)
11. Minden, K.: What are the costs of childhood-onset rheumatic disease? Best Pract. Res. Clin. Rheumatol. 20(2), 223–240 (2006)
12. Minier, T., Péntek, M., Brodszky, V., Ecseki, A., Kárpáti, K., Polgár, A., Czirják, L., Gulácsi, L.: Cost-of-illness of patients with systemic sclerosis in a tertiary care centre. Rheumatology (Oxford) 49(10), 1920–1928 (2010)
13. Linertová, R., Serrano-Aguilar, P., Posada-de-la-Paz, M., Hens-Pérez, M., Kanavos, P., Taruscio, D., Schieppati, A., Stefanov, R., Péntek, M., Delgado, C., von der Schulenburg, J.M., Persson, U., Chevreul, K., Fattore, G., Worbes-Cerezo, M., Sefton, M., López-Bastida, J., BURQOL-RD Research Group: Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study. Health Policy 108(1), 19–26 (2012)
14. Serrano-Aguilar P, Linertova R, Posada-de-la-Paz M, López-Bastida J, González-Hernández N, Taruscio D, BURQOL-RD Research Network. Recruitment procedures for descriptive socio-economic studies in rare diseases. The BURQOL-RD Project. Exp. Opin. Orphan Drugs 2015; 3(7):759–765
15. Association française pour le dépistage et la prévention des handicaps de l’enfant: Bilan d’activité 2012 (2013)
16. Chevreul K, Michel M, Berg-Brigham K et al. Social economic costs and health-related quality of life in patients with cystic fibrosis in Europe. Euro. J. Health Econ.
17. Whittington, J.E., Holland, A.J., Webb, T., Butler, J., Clarke, D., Boer, H.: Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health Region. Med. Genet. 38, 792–798 (2001)
18. Vogels, A., Van Den Ende, J., Keymolen, K., Mortier, G., Devriendt, K., Legius, E., Fryns, J.P.: Minimum prevalence, birth incidence and cause of death for Prader-Willi syndrome in Flanders. Eur. J. Hum. Genet. 12, 238–240 (2004)
19. Lopez-Bastida J, Linertová R, Oliva-Moreno J et al. Social economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe. Euro. J. Health Econ. 9, 37 (2014)
20. Rosendal FR, Briet E. The increasing prevalence of haemophilia. Thromb Haemostasis 1990; 63: 145. World Federation of Hemophilia, Report on the Annual Global Survey 2012; 2012. http://www1.wfh.org/publications/files/pdf-1574.pdf. Last accessed August 2015
21. Evatt, B.L.: Demographics of haemophilia in developing countries. Semin. Thromb. Hemostasis 31, 489–494 (2005)
22. Stonebraker, J.S., Bolton-Maggs, P.H.B., Michael Soucie, J., et al.: A study of variations in the reported haemophilia. A prevalence around the world. Haemophilia 16, 20–32 (2010)
23. DeJager, T., Pericleous, L., KoKot-Kierapa, M., et al.: Burden and management of factor XIII deficiency. Haemophilia 20, 733–740 (2014)
24. Cavazza M, Kodra Y, Armeni P. Social economic costs and quality of life in patients with haemophilia in Europe. Euro. J. Health Econ.
25. Mah, J.K., Korngu, L., Dykeman, J., Day, L., Pringsheim, T., Pringsheim, N.: A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul. Disord. 24, 482–491 (2014)
26. Kieny, P., Chollet, S., Delalande, P., Le, Fort M., Magot, A., Pereon, Y., Perrouin Verbe, B.: Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011. Ann. Phys. Rehabil. Med. 56, 443–454 (2013)
27. Emery, A.E.: Muscular dystrophy into the new millennium. Neuromuscul. Disord. 12, 343–349 (2002)
28. Cavazza M, Kodra Y, Armeni P et al. Social economic costs and health-related quality of life in patients with duchenne muscular dystrophy in Europe. Euro. J. Health Econ.
29. Fine, J.-D., et al.: The classification of inherited epidermolysis bullosa (EB): report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J. Am. Acad. Dermatol. 58(6), 931–950 (2008)
30. Orphanet Report Series. Prevalence of rare diseases: bibliographic data. (2013)
31. Angelis A, Kanavos P, López-Bastida J et al. Social economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe. Euro. J. Health Econ.
32. Bassell, G.J., Warren, S.T.: Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 60, 201–214 (2008)
33. Crawford, D.C., Acuña, J.M., Sherman, S.L.: FMR1 and the fragile X syndrome: human genome epidemiology review. Genet. Med. Off. J. Am. Coll. Med. Genet. 3, 359–371 (2001)
34. Orphanet Report Series—Prevalence of rare diseases: Bibliographic data., http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_decreasing_prevalence_or_cases.pdf (2013)
35. Chevreul K, Michel M, Berg-Brigham K et al. Social economic costs and health-related quality of life in patients with fragile X syndrome in Europe. Euro. J. Health Econ.
36. Chifflot, H., Fautrel, B., Sordet, C., Chatelus, E., Sibilia, J.: Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin. Arthritis Rheum. 37, 223–235 (2008)
37. Czirjak, L., Kiss, C.G., Lovei, C., Suto, G., Varju, C., Fuzesi, Z., et al.: Survey of Raynaud’s phenomenon and systemic sclerosis based on a representative study of 10,000 South-Transdanubian Hungarian inhabitants. Clin. Exp. Rheumatol. 23, 801–808 (2005)
38. Villaverde-Hueso, A., de la Paz, M.P., Martin-Arribas, M.C., Sanchez-Valle, E., Ramirez-Gonzalez, A., Biairdi, P.: Prevalence of scleroderma in Spain: an approach for estimating rare disease prevalence using a disease model. Pharmacoepidemiol. Drug Saf. 17, 1100–1107 (2008)
39. Silman, A., Jannini, S., Symmons, D., Bacon, P.: An epidemiological study of scleroderma in the West Midlands. Br. J. Rheumatol. 27, 286–290 (1988)
40. Arias-Nunez, M.C., Llorca, J., Vazquez-Rodriguez, T.R., Gomez- Acebo, I., Miranda-Filloy, J.A., Martin, J., et al.: Systemic sclerosis in northwestern Spain: a 19-year epidemiologic study. Medicine (Baltimore) 87, 272–280 (2008)
41. Haustein, U.F., Ziegler, V., Zschunke, E., et al.: Progressive systemic sclerosis with silicosis in the German Democratic Republic. In: Black, C.M., Myers, A.R. (eds.) Systemic sclerosis (scleroderma), pp. 138–142. Gower, New York (1985)
42. Monaco, A.L., Bruschi, M., Corte, R.L., et al.: Epidemiology of systemic sclerosis in a district of northern Italy. Clin. Exp. Rheumatol. 29(Suppl. 65), S10–S14 (2011)
43. Allcock, R.J., Forrest, I., Corris, P.A., Crook, P.R., Griffiths, I.D.: A study of the prevalence of systemic sclerosis in northeast England. Rheumatology 43, 596–602 (2004)
44. Andréasson, K., Saxne, T., Bergknut, C., Hesselstrand, R., Englund, M.: Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and the proposed ACR-EULAR classification criteria. Ann. Rheum. Dis. 73(10), 1788–1792 (2014)
45. Lopez-Bastida J, Linertová R, Oliva-Moreno J et al. Social–economic costs and health-related quality of life in patients with systemic sclerosis in Europe. Euro. J. Health Econ.
46. Jurecka, A., Lugowska, A., Golda, A., Czartoryska, B., Tylki-Szymanska, A.: Prevalence rates of mucopolysaccharidoses in Poland. J. Appl. Genet. 56(2), 205–210 (2015). doi:10.1007/s13353-014-0262-5
47. Péntek M, Gulácsi L, Brodszky V et al. Social economic costs and health-related quality of life of mucopolysacharidosis patients and their caregivers in Europe. Euro. J. Health Econ.
48. Ravelli, A., Martini, A.: Juvenile idiopathic arthritis. Lancet 369(9563), 767–778 (2007). doi:10.1016/S0140-6736(07)60363-8
49. Kuhlmann A, Schmidt T, Treskova M, López-Bastida J et al. Social economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe. Euro. J. Health Econ.
50. Hervier, B., Haroche, J., Arnaud, L., Charlotte, F., Donadieu, J., et al.: Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood 124, 1119–1126 (2014)
51. Histiocytosis Association: LCH in Children. http://www.histio.org/lchinchildren#.VJkyssgA. Accessed 23 December 2014
52. Stålemark, H., Laurencikas, E., Karis, J., Gavhed, D., Fadeel, B., et al.: Incidence of Langerhans cell histiocytosis in children: a population-based study. Pediatr. Blood Cancer 51, 76–81 (2008)
53. Iskrov G, Astigarraga I, Stefanov R et al. Social economic costs and health-related quality of life in patients with histiocytosis in Europe. Euro. J. Health Econ.